Literature DB >> 26151358

B7‑H3 promotes cell migration and invasion through the Jak2/Stat3/MMP9 signaling pathway in colorectal cancer.

Fen Liu1, Ting Zhang1, Shitao Zou1, Bo Jiang2, Dong Hua1.   

Abstract

B7‑H3, a newly identified co‑stimulatory molecule, has been reported to be highly expressed in a number of types of cancer and is associated with a poor prognosis. Transwell experiments and a wound-healing assay were used to detect the role of over‑expressed B7‑H3 on cell migration and invasion in colorectal cancer (CRC) cells. The expression level of matrix metallopeptidase 9 (MMP‑9) was further investigated by zymography experiments and western blot analysis, and involvement of the Janus kinase 2 (Jak2) signal transducer and activator of transcription 3 (STAT3) signaling pathway was determined using AG490, a Jak2 selective inhibitor. Data showed that overexpression of B7‑H3 promoted cell migration and invasion in CRC. Further investigation certified that enhanced expression of B7‑H3 elevated MMP‑9 through upregulation of the Jak2Stat3 signaling pathway. Due to its pro‑migratory and pro‑invasive function, B7‑H3 may serve as a therapeutic target in the treatment of CRC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26151358     DOI: 10.3892/mmr.2015.4050

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  29 in total

1.  Phenethyl isothiocyanate suppresses the metastasis of ovarian cancer associated with the inhibition of CRM1-mediated nuclear export and mTOR-STAT3 pathway.

Authors:  Wen Yu Shao; Yong Liang Yang; Huan Yan; Qian Huang; Kai Jiang Liu; Shu Zhang
Journal:  Cancer Biol Ther       Date:  2016-12-16       Impact factor: 4.742

2.  B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway.

Authors:  Bo Jiang; Fen Liu; ZhiHui Liu; Ting Zhang; Dong Hua
Journal:  Tumour Biol       Date:  2016-01-20

3.  Failed immune responses across multiple pathologies share pan-tumor and circulating lymphocytic targets.

Authors:  Anne Monette; Antigoni Morou; Nadia A Al-Banna; Louise Rousseau; Jean-Baptiste Lattouf; Sara Rahmati; Tomas Tokar; Jean-Pierre Routy; Jean-François Cailhier; Daniel E Kaufmann; Igor Jurisica; Réjean Lapointe
Journal:  J Clin Invest       Date:  2019-03-26       Impact factor: 14.808

4.  A three-phase trans-ethnic study reveals B7-H3 expression is a significant and independent biomarker associated with colon cancer overall survival.

Authors:  Yuan Gao; Yu Xu; Meiqin Gao; Aimin Huang; Pan Chi
Journal:  J Gastrointest Oncol       Date:  2021-12

5.  The Pituitary Tumors and Their Tumor-Specific Microenvironment.

Authors:  M M Kameda-Smith; J -Q Lu
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.

Authors:  Elodie Picarda; Kim C Ohaegbulam; Xingxing Zang
Journal:  Clin Cancer Res       Date:  2016-05-20       Impact factor: 12.531

7.  B7-H3 targeted antibody-based immunotherapy of malignant diseases.

Authors:  Theodoros Michelakos; Filippos Kontos; Omar Barakat; Luke Maggs; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Expert Opin Biol Ther       Date:  2020-12-21       Impact factor: 4.388

8.  CD276 is an important player in macrophage recruitment into the tumor and an upstream regulator for PAI-1.

Authors:  Sibel Durlanik; Katrin Fundel-Clemens; Coralie Viollet; Heinrich J Huber; Martin Lenter; Kerstin Kitt; Stefan Pflanz
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

Review 9.  B7-H3: An Attractive Target for Antibody-based Immunotherapy.

Authors:  Filippos Kontos; Theodoros Michelakos; Tomohiro Kurokawa; Ananthan Sadagopan; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Clin Cancer Res       Date:  2020-10-13       Impact factor: 13.801

10.  The co-stimulatory molecule B7-H3 promotes the epithelial-mesenchymal transition in colorectal cancer.

Authors:  Bo Jiang; Ting Zhang; Fen Liu; Zhangzhang Sun; Hanping Shi; Dong Hua; Chen Yang
Journal:  Oncotarget       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.